{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:44:42Z","timestamp":1789764282271,"version":"4.0.1"},"reference-count":63,"publisher":"FapUNIFESP (SciELO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dement. neuropsychol."],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>ABSTRACT Huntington's disease (HD) is an autosomal dominant neurodegenerative disease classified under the choreas. Besides motor symptoms, HD is marked by cognitive and behavioral symptoms, impacting patients' functional capacity. The progression of cognitive impairment and neuropsychiatric symptoms occur in parallel with neurodegeneration. The nature of these symptoms is very dynamic, and the major clinical challenges include executive dysfunction, apathy, depression and irritability. Herein, we provide a focused updated review on the cognitive and psychiatric features of HD.<\/jats:p>","DOI":"10.1590\/s1980-5764-2016dn1004002","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T18:44:06Z","timestamp":1482345846000},"page":"261-266","source":"Crossref","is-referenced-by-count":31,"title":["Revisiting the neuropsychiatry of Huntington's disease"],"prefix":"10.1590","volume":"10","author":[{"given":"Antonio Lucio","family":"Teixeira","sequence":"first","affiliation":[{"name":"Universidade Federal de Minas Gerais,  Brazil; University of Texas,  USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Cruz de","family":"Souza","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Pessoa","family":"Rocha","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais,  Brazil; University of Texas,  USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Furr-Stimming","sequence":"additional","affiliation":[{"name":"University of Texas,  USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Lauterbach","sequence":"additional","affiliation":[{"name":"Mercer University,  USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"issue":"9557","key":"ref1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker FO","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ncl.2009.04.001","article-title":"Huntington disease and other choreas","volume":"27","author":"Cardoso F","year":"2009","journal-title":"Neurol Clin"},{"issue":"8","key":"ref3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/01.WNL.0000086373.32347.16","article-title":"Huntington Study Group Huntington's disease: clinical correlates of disability and progression","volume":"61","author":"Mahant N","year":"2003","journal-title":"Neurology"},{"issue":"12","key":"ref4","first-page":"1520","article-title":"Natural history of Huntington disease","volume":"70","author":"Dorsey ER","year":"2013","journal-title":"JAMA Neurol"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0924-9338(01)00604-6","article-title":"Huntington's disease a review of the literature on prevalence and treatment of neuropsychiatric phenomena","volume":"16","author":"Naarding P","year":"2001","journal-title":"Eur Psychiatry"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/jnnp.37.2.121","article-title":"The 'subcortical dementia' of progressive supranuclear palsy","volume":"37","author":"Albert ML","year":"1974","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1-2","key":"ref7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jns.2009.08.036","article-title":"Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy","volume":"289","author":"Kertesz A","year":"2010","journal-title":"J Neurol Sci"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cortex.2012.07.001","article-title":"Beyond cortical localization in clinico-anatomical correlation","volume":"48","author":"Catani M","year":"2012","journal-title":"Cortex"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ana.20368","article-title":"Imaging connectivity in the human cerebral cortex the next frontier?","volume":"57","author":"Mesulam M","year":"2005","journal-title":"Ann Neurol"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/jnnp-2012-304558","article-title":"Beyond and below the cortex the contribution of striatal dysfunction to cognition and behaviour in neurodegeneration","volume":"85","author":"O'Callaghan C","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","article-title":"Cognitive impairment in Huntington disease diagnosis and treatment","volume":"11","author":"Paulsen JS","year":"2011","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/mds.22953","article-title":"Cognitive and functional decline in Huntington's disease dementia criteria revisited","volume":"25","author":"Peavy GM","year":"2010","journal-title":"Mov Disord"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0020937","article-title":"Neurocognitive signs in prodromal Huntington disease","volume":"25","author":"Stout JC","year":"2011","journal-title":"Neuropsychology"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/jnnp-2011-301940","article-title":"Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and earlyHuntington's disease","volume":"83","author":"Stout JC","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archneur.1993.00540040036010","article-title":"Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases","volume":"50","author":"Pillon B","year":"1993","journal-title":"Arch Neurol"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1212\/WNL.45.8.1477","article-title":"The neuropsychological pattern of corticobasal degeneration comparison with progressive supranuclear palsy and Alzheimer's disease","volume":"45","author":"Pillon B","year":"1995","journal-title":"Neurology"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.neuropsychologia.2006.12.015","article-title":"Predict-HD investigators of the Huntington Study Group Verbal episodic memory declines prior to diagnosis in Huntington's disease","volume":"45","author":"Solomon AC","year":"2007","journal-title":"Neuropsychologia"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/brain\/awh472","article-title":"The role of the striatum in rule application the model of Huntington's disease at early stage","volume":"128","author":"Teichmann M","year":"2005","journal-title":"Brain"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1590\/S0004-282X2012000600006","article-title":"Language impairment in Huntington's disease","volume":"70","author":"Azambuja MJ","year":"2012","journal-title":"Arq Neuropsiquiatr"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/brain\/awm107","article-title":"Predict-HD Investigators of the Huntington Study Group. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease","volume":"130","author":"Johnson SA","year":"2007","journal-title":"Brain"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1037\/a0024408","article-title":"Evidence for deficits on different components of theory of mind in Huntington's disease","volume":"25","author":"Allain P","year":"2011","journal-title":"Neuropsychology"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1037\/neu0000190","article-title":"Theory of mind can be impaired prior to motor onset in Huntington's disease","volume":"29","author":"Eddy CM","year":"2015","journal-title":"Neuropsychology"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1037\/neu0000224","article-title":"Do I misconstrue Sarcasm detection, emotion recognition, and theory of mind in Huntington disease","volume":"30","author":"Larsen IU","year":"2016","journal-title":"Neuropsychology"},{"issue":"7","key":"ref24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"TRACK-HD Investigators Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi SJ","year":"2013","journal-title":"Lancet Neurol"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S1474-4422(13)70105-4","article-title":"Huntington's disease the road to progress","volume":"12","author":"Walker FO","year":"2013","journal-title":"Lancet Neurol"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jns.2005.07.007","article-title":"Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy a neuropsychological and voxel-based morphometric study","volume":"239","author":"Peinemann A","year":"2005","journal-title":"J Neurol Sci"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/hbm.22055","article-title":"The structural correlates of functional deficits in early Huntington's disease","volume":"34","author":"Delmaire C","year":"2013","journal-title":"Hum Brain Mapp"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross CA","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1017\/S1355617713000507","article-title":"PREDICT-HD Investigators and Coordinators of the Huntington Study Group Cognitive reserve and brain reserve in prodromal Huntington's disease","volume":"19","author":"Bonner-Jackson A","year":"2013","journal-title":"J Int Neuropsychol Soc"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-0447.1994.tb01587.x","article-title":"Psychopathology in Huntington's disease patients","volume":"90","author":"Shiwach R","year":"1994","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0165-1781(01)00257-8","article-title":"Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers","volume":"102","author":"Berrios GE","year":"2001","journal-title":"Psychiatry Res"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.410360412","article-title":"Trinucleotide repeat length and rate of progression of Huntington's disease","volume":"36","author":"Illarioshkin SN","year":"1994","journal-title":"Ann Neurol"},{"issue":"4","key":"ref33","first-page":"219","article-title":"Behavioral changes in Huntington Disease","volume":"14","author":"Craufurd D","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.genhosppsych.2007.11.005","article-title":"Behavioural problems in Huntington's disease using the Problem Behaviours Assessment","volume":"30","author":"Kingma EM","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1176\/jnp.23.4.jnp399","article-title":"European Huntington's Disease Network Discriminant analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington's disease","volume":"23","author":"Rickards H","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","article-title":"European Huntington's Disease Network Behavioural Phenotype Working Group Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY)","volume":"85","author":"van Duijn E","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1176\/appi.ajp.2015.14121551","article-title":"PREDICT-HD Investigators and Coordinators of the Huntington Study Group Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data","volume":"173","author":"Epping EA","year":"2016","journal-title":"Am J Psychiatry"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2016.02.008","article-title":"Spanish REGISTRY investigators of the European Huntington's Disease Network, Kulisevsky J Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease","volume":"25","author":"Martinez-Horta S","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"ref39","first-page":"238","article-title":"Apathy in Alzheimer's disease","volume":"28","author":"Teixeira AL","year":"2006","journal-title":"Rev Bras Psiquiatr"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jad.2013.06.001","article-title":"REGISTRY investigators of the European Huntington's Disease Network Suicidal ideation in a European Huntington's disease population","volume":"151","author":"Hubers AA","year":"2013","journal-title":"J Affect Disord"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmg.30.4.293","article-title":"Suicide risk in Huntington's disease","volume":"30","author":"Di Maio L","year":"1993","journal-title":"J Med Genet"},{"issue":"6","key":"ref42","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1176\/ajp.140.6.728","article-title":"Psychiatric syndromes in Huntington's disease","volume":"140","author":"Caine ED","year":"1983","journal-title":"Am J Psychiatry"},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1155\/2013\/705373","article-title":"The pathophysiology and pharmacological treatment of Huntington disease","volume":"26","author":"Pidgeon C1","year":"2013","journal-title":"Behav Neurol"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.26007","article-title":"Targets for future clinical trials in Huntington's disease what's in the pipeline?","volume":"29","author":"Wild EJ","year":"2014","journal-title":"Mov Disord"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamaneurol.382","article-title":"A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease","volume":"70","year":"2013","journal-title":"JAMA Neurol"},{"issue":"3","key":"ref46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease","volume":"57","year":"2001","journal-title":"Neurology"},{"issue":"13","key":"ref47","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/mds.23236","article-title":"A futility study of minocycline in Huntington's disease","volume":"25","year":"2010","journal-title":"Mov Disord"},{"issue":"6","key":"ref48","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"American Academy of Neurology Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology","volume":"79","author":"Armstrong MJ","year":"2012","journal-title":"Neurology"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","article-title":"Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders","volume":"11","author":"Jankovic J","year":"2011","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"ref50","first-page":"CD006456","article-title":"Therapeutic interventions for symptomatic treatment in Huntington's disease","author":"Mestre T","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-5-18","article-title":"Tetrabenazine is neuroprotective in Huntington's disease mice","volume":"5","author":"Wang H","year":"2010","journal-title":"Mol Neurodegener"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/nmt.14.58","article-title":"Cognitive interventions to enhance neural compensation in Huntington's disease","volume":"5","author":"Andrews SC","year":"2015","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"ref53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment of Huntington's disease","volume":"11","author":"Frank S","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2011.10.021","article-title":"An evidence-based approach in the treatment of Huntington's disease","volume":"18","author":"Mestre TA","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/mds.25980","article-title":"Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease","volume":"29","author":"Moulton CD","year":"2014","journal-title":"Mov Disord"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2015.10.033","article-title":"Antidepressants for neuroprotection in Huntington's disease A review","volume":"769","author":"Jamwal S","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"ref57","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3233\/JHD-150143","article-title":"EHDN Registry Study Group Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease","volume":"4","author":"Tedroff J","year":"2015","journal-title":"J Huntingtons Dis"},{"issue":"5","key":"ref58","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/JCP.0b013e3181b2ac0a","article-title":"Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease","volume":"29","author":"Beglinger LJ","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"ref59","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","article-title":"Effect of donepezil on motor and cognitive function in Huntington disease","volume":"67","author":"Cubo E","year":"2006","journal-title":"Neurology"},{"key":"ref60","first-page":"CD009444","article-title":"Cholinesterase inhibitors for rarer dementias associated with neurological conditions","volume":"3","author":"Li Y","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"ref61","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.parkreldis.2006.08.005","article-title":"A pilot study of the clinical efficacy and safety of memantine for Huntington's disease","volume":"13","author":"Ondo WG","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"ref62","first-page":"239","article-title":"Cognitive function in early clinical phase huntington disease after rivastigmine treatment","volume":"26","author":"Se\u0161ok S","year":"2014","journal-title":"Psychiatr Danub"},{"issue":"1","key":"ref63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(14)70262-5","article-title":"Safety, tolerability, and efficacy of PBT2 in Huntington's disease a phase 2, randomised, double-blind, placebo-controlled trial","volume":"14","year":"2015","journal-title":"Lancet Neurol"}],"container-title":["Dementia &amp; Neuropsychologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/dn\/v10n4\/1980-5764-dn-10-04-00261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T22:15:05Z","timestamp":1495577705000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1980-57642016000400261&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1980-57642016000400261"],"URL":"https:\/\/doi.org\/10.1590\/s1980-5764-2016dn1004002","relation":{},"ISSN":["1980-5764"],"issn-type":[{"value":"1980-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}